BioSim™ Avelumab (Bavencio®) (Human) ELISA Kit

Avelumab (Bavencio®) is a fully human anti-PD-L1 IgG1 lambda monoclonal antibody that has a molecular weight of approximately 147 kDa. Avelumab binds PD-L1 and blocks the interaction between PD-L1 and its receptors PD-1 and B7-1. By inhibiting PD-L1 interactions, avelumab is thought to enable the activation of T-cells and the adaptive immune system. By retaining anative Fc-region, avelumab is thought to engage the innate immune system and may induce antibody-dependent cell-mediated cytotoxicity. Importantly, avelumab has not shown antibody-dependent cellmediated cytotoxicity against immune cell subsets in humans. BioSim™ Avelumab ELISA kit has been developed for specific quantification of Avelumab concentration in human serum or plasma with high sensitivity and reproducibility.